ACM
CGEM icon

ADAR1 Capital Management’s Cullinan Oncology CGEM Stock Holding History

ADAR1 Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$711K – 291
2026
Q1 		$711K Hold
50,000
– – 0.04% 185
2025
Q4 		$518K Buy
+50,000
New +$451K 0.04% 181
2024
Q4 		– Sell
-54,358
Closed -$910K – 236
2024
Q3 		$910K Buy
54,358
+1,097
+2% +$19.5K 0.15% 85
2024
Q2 		$929K Buy
+53,261
New +$1.13M 0.18% 67

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ADAR1 Capital Management's CGEM Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Cullinan Oncology (CGEM) in Q2 2026, closing a stake of 50,000 shares — an estimated $711K sold.

ADAR1 Capital Management first reported a position in CGEM in Q2 2024 and held it in 4 quarters. The position peaked at $929K in Q2 2024. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Cullinan Oncology position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 50,000 Cullinan Oncology shares in Q2 2026, an estimated $711K.
  • ADAR1 Capital Management first reported a position in Cullinan Oncology in Q2 2024 and held it in 4 quarters.
  • ADAR1 Capital Management's Cullinan Oncology position peaked at $929K in Q2 2024.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.